MaYingLong Pharmaceutical (600993): Investment Income Reduced

  • Contributor:TX Investment Consulting
  • Date:Jul 30, 2008
  • Pages:3pages
  • Price:$20.00
  • File Type: Adobe Acrobat Reader®
Download Free Adobe Acrobat Reader®

Research Reports Premium Services

-Get the full report for $20.00

-The financial products you have ordered will be sent to   you within 24 hours via e-mail.

Excerpts:

For the first 6 months of 2008, the company achieved operating income of Rmb351mn, an increase of 32.59% yoy; operating profit: Rmb57.79mn, down 54.43% yoy; net profit contributed to the parent company: Rmb47.76mn, decreasing 46.42%; diluted EPS: Rmb0.52. Future focus of the company will be on the development of its main business. Its first specialized hospital will be opened by the end of this year. We expect 2008-2010 diluted EPS of the company to be Rmb0.83, Rmb1.17 and Rmb1.37. "Overweight" investment rating is given.


SSL